Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine ER in Uremic Pruritus
NCT02143648Phase 3Completed
- Sponsor
- Trevi Therapeutics
- Start
- Jun 2014
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of nalbuphine in uremic pruritus, sponsored by Trevi Therapeutics. Started Jun 2014; status: completed.
02
Drugs
nalbuphine
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT02143648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143648.